Cost Analysis of Antiretroviral Treatment in Germany
Author Information
Author(s): Matthias Stoll, Christian Kollan, Frank Bergmann, Johannes Bogner, Gerd Faetkenheuer, Carlos Fritzsche, Kirsten Hoeper, Heinz-August Horst, Jan van Lunzen, Andreas Plettenberg, Stefan Reuter, Jürgen Rockstroh, Hans-Jürgen Stellbrink, Osamah Hamouda, Barbara Bartmeyer, ClinSurv Study Group
Primary Institution: Robert Koch Institute
Hypothesis
The availability of generic drugs next to branded drugs in the same market would lead to a reduction in prices.
Conclusion
The study provides insights into the cost impacts of antiretroviral therapy and suggests potential cost-saving strategies through the use of generics.
Supporting Evidence
- Over 21 million treatment days were covered during the study.
- Cumulative direct costs for antiretroviral drugs were over €812 million.
- Potential savings of 10.9% to 19.8% were identified by substituting certain drugs.
- Direct costs of cART were lower for females compared to males.
- Mean daily drug costs increased by 13.5% over the study period.
Takeaway
This study looked at how much it costs to treat HIV in Germany and found that using generic drugs could save a lot of money.
Methodology
The study analyzed data from 10,190 HIV-infected patients over a 13-year period, focusing on treatment costs and potential savings from generics.
Potential Biases
The cohort may not represent all HIV patients in Germany, limiting generalizability.
Limitations
The study only focuses on direct costs and does not account for indirect or intangible costs.
Participant Demographics
Approximately 80% male, 75% German born, with over 60% symptomatic according to CDC classification.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website